Related Experiment Video
Updated: May 27, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer
1NutriGuard Research, 1051 Hermes Ave., Encinitas, CA 92024, USA. markfmccarty@gmail.com
Abstract:
Cancer cells with stem cell characteristics are harbored by most tumors, and are characterized by epithelial-mesenchymal transition (EMT) - which promotes invasive growth and metastasis - chemoresistance, and the capacity to reconstitute new tumors. Hence, the control or destruction of cancer stem cells should be a major goal of cancer management. The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness. It is therefore particularly intriguing that metformin, a diabetes drug thought to have potential in the prevention and treatment of cancer, has recently been found to oppose cancer cell stemness, to markedly potentiate chemotherapeutic control of cancer in mouse xenograft models, and to notably boost let-7a levels in cancer stem cells. It is proposed that this latter effect of metformin may reflect AMPK-mediated inhibition of the expression or activity of Lin28/Lin28A, proteins which act post-transcriptionally to decrease the levels of all let-7 family members. The transcription of Lin28B is promoted by NF-kappaB and by Myc; hence, practical measures which antagonize NF-kappaB or Myc activity may complement the utility of metformin for boosting let-7 expression and controlling cancer stemness; salsalate, antioxidants, tyrosine kinase and cox-2 inhibitors, ribavirin, vitamin D, gamma-secretase inhibitors (when available), and parenteral curcumin may have some utility in this regard. Although the impact of histone deacetylase inhibitors on let-7 expression has not been assessed, there is reason to suspect that these drugs might complement let-7's impact on chemoresistance, EMT, and stemness. Multifocal strategies centering on metformin may have considerable potential for reversing cancer stemness and rendering advanced cancers more susceptible to long term control.
Insights
Metformin, a diabetes drug, combats cancer stemness by increasing let-7 microRNA levels. This approach, targeting cancer stem cells, shows promise for improving cancer treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Most tumors contain cancer cells with stem cell characteristics, driving invasive growth, metastasis, and chemoresistance.
- Reduced levels of let-7 microRNAs are typical in cancer stem cells and may drive cancer stemness.
- Metformin, a diabetes drug, has shown potential in cancer prevention and treatment.
Purpose of the Study:
- To investigate metformin's effect on cancer stemness and let-7 microRNA levels.
- To explore the mechanisms by which metformin influences cancer stem cells.
- To identify complementary strategies for enhancing metformin's anti-cancer effects.
Main Methods:
- Investigated metformin's impact on cancer stemness in mouse xenograft models.
- Assessed metformin's effect on let-7a levels in cancer stem cells.
- Proposed mechanisms involving AMPK, Lin28/Lin28A, NF-kappaB, and Myc.
Main Results:
- Metformin opposed cancer cell stemness and potentiated chemotherapeutic control in xenograft models.
- Metformin significantly increased let-7a levels in cancer stem cells.
- Evidence suggests metformin's effects may be mediated by AMPK-dependent inhibition of Lin28/Lin28A.
Conclusions:
- Metformin shows potential for reversing cancer stemness and enhancing cancer treatment.
- Targeting Lin28/Lin28A and related pathways (NF-kappaB, Myc) could complement metformin therapy.
- Multifocal strategies involving metformin may improve long-term control of advanced cancers.
Related Concept Videos
MicroRNAs
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
